Breakthroughs and challenges in the management of pediatric viral hepatitis

Table 3 Antiviral drugs approved for adolescents and children with chronic hepatitis B virus infection

Drug	Use in children	Dose	Formulation
Interferon-α-2b	≥ 1 yr	6 million IU/m2 3 times a week	Subcutaneous injections
Pegylated interferon-α-2a	≥ 3 yr	180 µg/1.73 m2 once a week	Subcutaneous injections
Lamivudine	≥ 3 yr	3 mg/kg daily (max 100 mg)	Oral solution (5 mg/mL)
			tablets (100 mg)
Entecavir	≥ 2 yr	10-30 kg: 0.015 mg/kg daily (max 0·5 mg)	Oral solution (0.05 mg/mL)
			tablets (0.5 mg and 1 mg)
Adefovir	≥ 12 yr	10 mg daily	Tablets (10 mg)
Tenofovir disoproxil fumarate	≥ 12 yr (FDA)	300 mg daily	Oral powder (40 mg per 1 g)
	≥ 2 yr (EMA)		tablets (150, 200, 250 and 300 mg)
Tenofovir alafenamide	≥ 12 yr (EMA)	25 mg daily	Tablets (25 mg)

EMA: European Medicines Agency; FDA: Food and Drug Administration.